PI-103 for multi-drug resistance of leukemia cells in vitro.doc

 PAGE \* MERGEFORMAT 11 PI-103 for multi-drug resistance of leukemia cells in vitro [Abstract] Objective To study the PI-103 on drug effect and mechanism of leukemic cells. Methods tetrazolium blue (MTT method and the PI-103 K562/A02 K562 cell proliferation, flow cytometry intracellular adriamycin concentration changes. Results PI-103 could significantly inhibit the growth of both cell lines, sensitive and resistant leukemia cell lines have the same inhibitory effect, PI-103 can significantly increase the concentration of intracellular adriamycin , and doxorubicin, can increase the adriamycin on cell growth inhibition, but only without the superimposed effect of synergy. Conclusion PI-103 drug-resistant leukemia is a good prospect of the drug. [Keywords:] multidrug resistance PI-103 Multidrug resistance is the main reason for treatment failure in acute leukemia, the main mechanism of P-glycoprotein (Pgp is highly expressed within the cells of chemotherapy drugs “pump” the cells, lead to intracellular drug concentration is too low, the leukemia cells showing a resistance phenotype. how to bypass the role of Pgp pump, reverse the drug resistance and improve the treatment of leukemia is an important direction for the current treatment of K562 cells by .K562/A02 adriamycin induced by long-established screening and cloning A resistant cell lines [1], can survive for long in the 2g/ml doxorubicin, adriamycin resistance index of 10 or more. its high expression of Pgp, multidrug resistance in vitro study is a good cell model. PI-103 is a synthetic specific inhibitor of PI3K and mTOR. PI3K and mTOR signaling pathway is PI3K/AKT/mTOR an important member of the signaling pathways in tumor development play an important role. In recent years, to discover the PI-103 on melanoma [2], lung [3], neural tumors [4] and other tumors inhibited, showing a good anti-tumor effect. This study aimed to study its multi-drug resistance The role of leukemia cell lin